Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings
Alejandra Maciel, Ali Cullors, Andrew A. Lukowiak, et al.
Neuropsychiatric Disease and Treatment (2018) Vol. Volume 14, pp. 225-230
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study
John F. Greden, Sagar V. Parikh, Anthony J. Rothschild, et al.
Journal of Psychiatric Research (2019) Vol. 111, pp. 59-67
Open Access | Times Cited: 268
Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good
Kristi Krebs, Lili Milani
Human Genomics (2019) Vol. 13, Iss. 1
Open Access | Times Cited: 157
Review and Consensus on Pharmacogenomic Testing in Psychiatry
Chad A. Bousman, Susanne Bengesser, Katherine J. Aitchison, et al.
Pharmacopsychiatry (2020) Vol. 54, Iss. 01, pp. 5-17
Open Access | Times Cited: 148
Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review
Sarah Morris, Ashraf T. Alsaidi, Allison Verbyla, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 112, Iss. 6, pp. 1318-1328
Open Access | Times Cited: 82
Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders
Stacey L. Aldrich, Ethan A. Poweleit, Cynthia A. Prows, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 92
Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions
Sulev Reisberg, Kristi Krebs, Maarja Lepamets, et al.
Genetics in Medicine (2018) Vol. 21, Iss. 6, pp. 1345-1354
Open Access | Times Cited: 89
Pharmacogenetics in Psychiatry: An Update on Clinical Usability
Ron H. N. van Schaik, Daniel J. Müller, Alessandro Serretti, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 70
Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of Big Data
Dragan Primorac, Lidija Bach‐Rojecky, Dalia Vađunec, et al.
Pharmacogenomics (2020) Vol. 21, Iss. 2, pp. 141-156
Open Access | Times Cited: 55
Economic evaluation in psychiatric pharmacogenomics: a systematic review
Kariofyllis Karamperis, Maria Koromina, Panagiotis Papantoniou, et al.
The Pharmacogenomics Journal (2021) Vol. 21, Iss. 4, pp. 533-541
Open Access | Times Cited: 45
Okra Improvement in Egypt and North Africa: Current Status and Opportunities
Ehab A. Ibrahim, Hamdino M. I. Ahmed
(2025), pp. 125-147
Closed Access
Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future
Chiara Fabbri, Alessandro Serretti
Clinical Psychopharmacology and Neuroscience (2020) Vol. 18, Iss. 1, pp. 1-9
Open Access | Times Cited: 29
The impact of pharmacogenetic testing in patients exposed to polypharmacy: a scoping review
Erika L. Meaddough, Sara M. Sarasua, Tracy Fasolino, et al.
The Pharmacogenomics Journal (2021) Vol. 21, Iss. 4, pp. 409-422
Closed Access | Times Cited: 26
Gene-drug pairings for antidepressants and antipsychotics: level of evidence and clinical application
Lara Murphy, Trehani M. Fonseka, Chad A. Bousman, et al.
Molecular Psychiatry (2021) Vol. 27, Iss. 1, pp. 593-605
Closed Access | Times Cited: 22
Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study
Marco Calabrò, Chiara Fabbri, Siegfried Kasper, et al.
European Neuropsychopharmacology (2022) Vol. 56, pp. 100-111
Closed Access | Times Cited: 14
Acceptability of Pharmacogenetic Testing among French Psychiatrists, a National Survey
Benjamin Laplace, Benjamin Calvet, Aurélie Lacroix, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 6, pp. 446-446
Open Access | Times Cited: 18
Approaches and hurdles of implementing pharmacogenetic testing in the psychiatric clinic
Abdullah Al Maruf, Chad A. Bousman
Psychiatry and Clinical Neurosciences Reports (2022) Vol. 1, Iss. 2
Closed Access | Times Cited: 13
<p>Concepts Driving Pharmacogenomics Implementation Into Everyday Healthcare</p>
Jyothsna Giri, Ann M. Moyer, Suzette J. Bielinski, et al.
Pharmacogenomics and Personalized Medicine (2019) Vol. Volume 12, pp. 305-318
Open Access | Times Cited: 20
Cost Avoidance Related to a Pharmacist-Led Pharmacogenomics Service for the Program of All-inclusive Care for the Elderly
K.T. Bain, Calvin H. Knowlton, Adriana Matos
Pharmacogenomics (2020) Vol. 21, Iss. 10, pp. 651-661
Closed Access | Times Cited: 18
Digital Microfluidics-Enabled Analysis of Individual Variation in Liver Cytochrome P450 Activity
Gowtham Sathyanarayanan, Markus Haapala, Tiina Sikanen
Analytical Chemistry (2020) Vol. 92, Iss. 21, pp. 14693-14701
Closed Access | Times Cited: 11
Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression
Chiara Fabbri, Siegfried Kasper, Joseph Zohar, et al.
Journal of Affective Disorders (2020) Vol. 279, pp. 722-729
Open Access | Times Cited: 11
Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.

PubMed (2021) Vol. 21, Iss. 13, pp. 1-214
Closed Access | Times Cited: 10
Identification of high-impact gene–drug pairs for pharmacogenetic testing in Alberta, Canada
Mikayla Fan, Mark Yarema, Adrian Box, et al.
Pharmacogenetics and Genomics (2020) Vol. 31, Iss. 2, pp. 29-39
Closed Access | Times Cited: 9
Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions
Sulev Reisberg, Kristi Krebs, Mart Kals, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2018)
Open Access | Times Cited: 9
Costing Methods as a Means to Measure the Costs of Pharmacogenomics Testing
Stavroula Siamoglou, Kariofyllis Karamperis, Christina Mitropoulou, et al.
The Journal of Applied Laboratory Medicine (2020) Vol. 5, Iss. 5, pp. 1005-1016
Open Access | Times Cited: 8
Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)
Efthimios Bothos, E. Ntoumou, K. Kelaidoni, et al.
Journal of Translational Medicine (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top